• Je něco špatně v tomto záznamu ?

A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models

M. Bamorovat, I. Sharifi, A. Fekri, A. Keyhani, MR. Aflatoonian, A. Heshmatkhah, RT. Oliaee, A. Khosravi, A. Naderi, MH. Parizi, M. Mostafavi, RS. Varma,

. 2019 ; 128 (-) : 162-170. [pub] 20181221

Jazyk angličtina Země Anglie, Velká Británie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc19012010

Currently, there is no satisfactory treatment modality available for cutaneous leishmaniasis (CL). The major objective of the present study was to explore the effect of immunomodulator-levamisole in combination with Glucantime in end-stage unresponsive patients with anthroponotic CL (ACL). Twenty end-stage unresponsive patients with ACL were identified for participation in this single-group trial study. Simultaneously, each patient was received a combination of levamisole pills along with Glucantime during the remedy course. Several in vitro complementary experiments were performed to evaluate the mode of action of levamisole and Glucantime alone and in combination using a macrophage model, in vitro MTT assay, flow cytometry and quantitative real time PCR (qPCR). Overall, 75% of the patients showed complete clinical cure, 10% partially improved and the remaining (15%) had underlying chronic diseases demonstrated no response to the treatment regimen. In in vitro studies, there was no cytotoxic effect associated with these drugs in the range of our experiments. The findings by the flow cytometric analysis represented that the highest apoptotic values corresponded to the drugs combination (32.23%) at 200 μg/ml concentration. Finally, the gene expression level of IL-12 p40, iNOS and TNF-α promoted while the level of IL-10 and TGF-β genes reduced as anticipated. The findings clearly indicated that the combination of levamisole and Glucantime should be considered in end-stage unresponsive patients with ACL who have not responded to basic treatments. The immunomodulatory role of levamisole in mounting immune system as documented by the in vitro experiments and further substantiated by this single-group trail study was highlighted.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19012010
003      
CZ-PrNML
005      
20190418084552.0
007      
ta
008      
190405s2019 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.micpath.2018.12.040 $2 doi
035    __
$a (PubMed)30583021
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Bamorovat, Mehdi $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
245    12
$a A single-group trial of end-stage patients with anthroponotic cutaneous leishmaniasis: Levamisole in combination with Glucantime in field and laboratory models / $c M. Bamorovat, I. Sharifi, A. Fekri, A. Keyhani, MR. Aflatoonian, A. Heshmatkhah, RT. Oliaee, A. Khosravi, A. Naderi, MH. Parizi, M. Mostafavi, RS. Varma,
520    9_
$a Currently, there is no satisfactory treatment modality available for cutaneous leishmaniasis (CL). The major objective of the present study was to explore the effect of immunomodulator-levamisole in combination with Glucantime in end-stage unresponsive patients with anthroponotic CL (ACL). Twenty end-stage unresponsive patients with ACL were identified for participation in this single-group trial study. Simultaneously, each patient was received a combination of levamisole pills along with Glucantime during the remedy course. Several in vitro complementary experiments were performed to evaluate the mode of action of levamisole and Glucantime alone and in combination using a macrophage model, in vitro MTT assay, flow cytometry and quantitative real time PCR (qPCR). Overall, 75% of the patients showed complete clinical cure, 10% partially improved and the remaining (15%) had underlying chronic diseases demonstrated no response to the treatment regimen. In in vitro studies, there was no cytotoxic effect associated with these drugs in the range of our experiments. The findings by the flow cytometric analysis represented that the highest apoptotic values corresponded to the drugs combination (32.23%) at 200 μg/ml concentration. Finally, the gene expression level of IL-12 p40, iNOS and TNF-α promoted while the level of IL-10 and TGF-β genes reduced as anticipated. The findings clearly indicated that the combination of levamisole and Glucantime should be considered in end-stage unresponsive patients with ACL who have not responded to basic treatments. The immunomodulatory role of levamisole in mounting immune system as documented by the in vitro experiments and further substantiated by this single-group trail study was highlighted.
650    _2
$a mladiství $7 D000293
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a zvířata $7 D000818
650    _2
$a antiprotozoální látky $x farmakologie $x terapeutické užití $7 D000981
650    _2
$a buněčné linie $x účinky léků $7 D002460
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a dítě $7 D002648
650    _2
$a chronická nemoc $x terapie $7 D002908
650    _2
$a fixní kombinace léků $7 D004338
650    _2
$a kombinovaná farmakoterapie $7 D004359
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a interleukin-10 $x metabolismus $7 D016753
650    _2
$a interleukin-12 - podjednotka p40 $x metabolismus $7 D053762
650    _2
$a Leishmania tropica $x účinky léků $x patogenita $7 D007895
650    _2
$a leishmanióza kožní $x farmakoterapie $7 D016773
650    _2
$a levamisol $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D007978
650    _2
$a makrofágy $x účinky léků $7 D008264
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a meglumin antimoniát $x aplikace a dávkování $x farmakologie $x terapeutické užití $7 D000077485
650    _2
$a myši $7 D051379
650    _2
$a lidé středního věku $7 D008875
650    _2
$a synthasa oxidu dusnatého, typ II $x metabolismus $7 D052247
650    _2
$a transformující růstový faktor beta $x metabolismus $7 D016212
650    _2
$a výsledek terapie $7 D016896
650    _2
$a TNF-alfa $x metabolismus $7 D014409
650    _2
$a mladý dospělý $7 D055815
655    _2
$a časopisecké články $7 D016428
700    1_
$a Sharifi, Iraj $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran. Electronic address: iraj.sharifi@yahoo.com.
700    1_
$a Fekri, Alireza $u Department of Dermatology, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Keyhani, Alireza $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Aflatoonian, Mohammad Reza $u Research Center of Tropical and Infectious Diseases, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Heshmatkhah, Amireh $u Dadbin Health Clinic, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Oliaee, Razieh Tavakoli $u Department of Medical Parasitology and Mycology, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Khosravi, Ahmad $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Naderi, Afsaneh $u Department of Medical Parasitology and Mycology, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Parizi, Maryam Hakimi $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Mostafavi, Mahshid $u Leishmaniasis Research Center, Kerman University of Medical Sciences, Kerman, Iran.
700    1_
$a Varma, Rajender S $u Regional Centre of Advanced Technologies and Materials, Faculty of Science, Palacký University in Olomouc, Šlechtitelů 27, 783 71, Olomouc, Czech Republic.
773    0_
$w MED00008641 $t Microbial pathogenesis $x 1096-1208 $g Roč. 128, č. - (2019), s. 162-170
856    41
$u https://pubmed.ncbi.nlm.nih.gov/30583021 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20190405 $b ABA008
991    __
$a 20190418084620 $b ABA008
999    __
$a ok $b bmc $g 1391320 $s 1050315
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2019 $b 128 $c - $d 162-170 $e 20181221 $i 1096-1208 $m Microbial pathogenesis $n Microb Pathog $x MED00008641
LZP    __
$a Pubmed-20190405

Najít záznam

Citační ukazatele

Nahrávání dat ...

    Možnosti archivace